1. |
Bae WK, Shim HJ, Choi YD, et al. Severe hypothyroidism indu-ced by thyroid metastasis of cholangiocarcinoma[J]. Cancer ResTreat, 2009, 41(1):56-58.
|
2. |
宋振顺, 范志勇, 窦科峰, 等. 肝门部胆管癌的诊断及治疗[J]. 中国实用外科杂志, 2009, 11(29):966-968.
|
3. |
Socoteanu MP, Mott F, Alpini G, et al. c-Met targeted therapy ofcholangiocarcinoma[J]. World J Gastroentero, 2008, 14(19):2990-2994.
|
4. |
杨晓洲, 王勇, 刘金钢. 细胞内信息传导与胆管癌的侵袭转移研究进展 [J]. 中国实用外科杂志, 2011, 31(6):530-532.
|
5. |
Ji H, Liu YE, Jia T, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing[J]. Cancer Res, 1997, 57(4):759-764.
|
6. |
Jia T, Liu YE, Liu J, et al. Stimulation of breast cancer invasion and metastasis by synuclein-γ[J]. Cancer Res, 1999, 59(3):742-747.
|
7. |
金琳芳, 吴玉玉, 陈进, 等. SNCG、nm23在胃癌中的表达及临床意义[J]. 现代肿瘤医学, 2010, 18(11):2196-2198.
|
8. |
Sing VK, Jia Z. Targeting synuclein-gamma to counteract drug resistance in cancer[J]. Expert Opin Ther Targets, 2008, 12(1):59-68.
|
9. |
Bruening W, Giasson BI, Klein-Szanto AJ, et al. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary[J]. Cancer, 2000, 88(9):2154-2163.
|
10. |
Zhao W, Liu H, Liu W, et al. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration[J]. Int J Oncol, 2006, 28(5):1081-1088.
|
11. |
Li Z, Sclabas GM, Peng B, et al. Overexpression of synucleingamma in pancreatic adenocarcinoma[J]. Cancer, 2004, 101(1):58-65.
|
12. |
Wu K, Quan Z, Weng Z, et al. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis[J]. Breast Cancer Ras Treatmen, 2007, 101(3):259-267.
|
13. |
徐卫东, 殷辉, 赵建国, 等. 原发性骨肉瘤中γ-Synuclein的表达[J]. 第二军医大学学报, 2007, 28(4):432-435.
|
14. |
Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States:a case control study[J]. Gastroenterology, 2005, 128 (3):620-626.
|
15. |
Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma:consensus document[J]. Gut, 2002, 51 Suppl 6:Ⅵ1-Ⅵ9.
|
16. |
Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma[J]. Lancet, 2005, 366(9493):1303-1314.
|
17. |
Liu XF, Zhou XT, Zou SQ. An analysis of 680 cases of cholangiocarcinoma from 8 hospitals [J]. Hepatobiliary Pancreat Dis Int, 2005, 4(4):585-588.
|
18. |
张惠卿, 张宇新, 张作风, 等. γ-synuclein在乳腺癌中的表达及意义[J]. 中国肿瘤临床, 2005, 32(1):9-12..
|
19. |
Yanagawa N, Tamura G, Honda L, et al. Demethylation of the synuclein gamma gene CpG island in primary gastric cancels and gastric cancers cell lines. CancerCell Lines[J]. Clin Cancer Res. 2004, 10(7):2447-2451.
|
20. |
Czekierdowski A, Czekierdowska S, Wielgos M, et al. The role of CpG islands hypomethylation and abnormal expression ofneuronal protein synuclein-gamma (SNCG) in ovarian cancer[J]. Neuro Endocrinol Lett, 2006, 27(3):381-386.
|
21. |
Iwaki H, Kageyama S, Isono T, et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis[J]. Cancer Sci, 2004, 95(12):955-961.
|
22. |
Liu H, Liu W, Wu Y, et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers[J]. Cancer Res, 2005, 65(17):7635-7643.
|
23. |
Hu H, Sun L, Guo C, et al. Tumor cell-microenvironment inter-action models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis[J]. Clin Cancer Res, 2009, 15(17):5485-5493.
|
24. |
Morgan J, Hoekstra AV, Chapman-Davis E, et al. Synuclein-γ(SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma[J]. Gynecol Oncol, 2009, 114(2):293-298.
|
25. |
Zhou CQ, Liu S, Xue LY, et al. Down-regulation of gamma-synuclein in human esophageal squamous cell carcinoma[J]. World J Gastroenterol, 2003, 9(9):1900-1903.
|